請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59518
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林水龍(Shuei-Liong Lin),朱宗信(Tzong-Shinn Chu) | |
dc.contributor.author | Yu-Hsiang Chou | en |
dc.contributor.author | 周鈺翔 | zh_TW |
dc.date.accessioned | 2021-06-16T09:26:23Z | - |
dc.date.available | 2022-09-08 | |
dc.date.copyright | 2017-09-08 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-06-05 | |
dc.identifier.citation | 1. Thomas ME, Blaine C, Dawnay A, Devonald MA, Ftouh S, Laing C, et al. The definition of acute kidney injury and its use in practice. Kidney Int. 2015;87:62-73
2. Lewington AJ, Cerda J, Mehta RL. Raising awareness of acute kidney injury: A global perspective of a silent killer. Kidney Int. 2013;84:457-67 3. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the rifle criteria for acute renal failure in hospitalized patients. Crit Care Med. 2006;34:1913-7 4. Chang JW, Jeng MJ, Yang LY, Chen TJ, Chiang SC, Soong WJ, et al. The epidemiology and prognostic factors of mortality in critically ill children with acute kidney injury in taiwan. Kidney Int. 2015;87:632-9 5. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. Kdoqi us commentary on the 2012 kdigo clinical practice guideline for the evaluation and management of ckd. Am J Kidney Dis. 2014;63:713-35 6. Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in taiwan. Nephrology (Carlton). 2010;15 Suppl 2:3-9 7. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: A prospective cohort study based on 462 293 adults in taiwan. Lancet. 2008;371:2173-82 8. Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011;79:1361-9 9. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. 2011;121:4210-21 10. Just A. Mechanisms of renal blood flow autoregulation: Dynamics and contributions. Am J Physiol Regul Integr Comp Physiol. 2007;292:R1-17 11. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365:417-30 12. Vetterlein F, Petho A, Schmidt G. Distribution of capillary blood flow in rat kidney during postischemic renal failure. Am J Physiol. 1986;251:H510-9 13. Olof P, Hellberg A, Kallskog O, Wolgast M. Red cell trapping and postischemic renal blood flow. Differences between the cortex, outer and inner medulla. Kidney Int. 1991;40:625-31 14. Molitoris BA, Sutton TA. Endothelial injury and dysfunction: Role in the extension phase of acute renal failure. Kidney Int. 2004;66:496-9 15. Donohoe JF, Venkatachalam MA, Bernard DB, Levinsky NG. Tubular leakage and obstruction after renal ischemia: Structural-functional correlations. Kidney Int. 1978;13:208-22 16. Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, Kirschning CJ, et al. Renal-associated tlr2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest. 2005;115:2894-903 17. Wahl P, Schoop R, Bilic G, Neuweiler J, Le Hir M, Yoshinaga SK, et al. Renal tubular epithelial expression of the costimulatory molecule b7rp-1 (inducible costimulator ligand). J Am Soc Nephrol. 2002;13:1517-26 18. Guo RF, Ward PA. Role of c5a in inflammatory responses. Annu Rev Immunol. 2005;23:821-52 19. Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371:58-66 20. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: A systematic review and meta-analysis. Kidney Int. 2012;81:442-8 21. Thakar CV, Christianson A, Himmelfarb J, Leonard AC. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol. 2011;6:2567-72 22. Heung M, Steffick DE, Zivin K, Gillespie BW, Banerjee T, Hsu CY, et al. Acute kidney injury recovery pattern and subsequent risk of ckd: An analysis of veterans health administration data. Am J Kidney Dis. 2016;67:742-52 23. Lai CF, Wu VC, Huang TM, Yeh YC, Wang KC, Han YY, et al. Kidney function decline after a non-dialysis-requiring acute kidney injury is associated with higher long-term mortality in critically ill survivors. Crit Care. 2012;16:R123 24. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in g2/m mediates kidney fibrosis after injury. Nat Med. 2010;16:535-43, 1p following 143 25. Wu CF, Chiang WC, Lai CF, Chang FC, Chen YT, Chou YH, et al. Transforming growth factor beta-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. Am J Pathol. 2013;182:118-31 26. Bechtel W, McGoohan S, Zeisberg EM, Muller GA, Kalbacher H, Salant DJ, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 2010;16:544-50 27. Zager RA, Johnson AC. Renal ischemia-reperfusion injury upregulates histone-modifying enzyme systems and alters histone expression at proinflammatory/profibrotic genes. Am J Physiol Renal Physiol. 2009;296:F1032-41 28. Bolisetty S, Agarwal A. Neutrophils in acute kidney injury: Not neutral any more. Kidney Int. 2009;75:674-6 29. Ysebaert DK, De Greef KE, Vercauteren SR, Ghielli M, Verpooten GA, Eyskens EJ, et al. Identification and kinetics of leukocytes after severe ischaemia/reperfusion renal injury. Nephrol Dial Transplant. 2000;15:1562-74 30. Lech M, Grobmayr R, Ryu M, Lorenz G, Hartter I, Mulay SR, et al. Macrophage phenotype controls long-term aki outcomes--kidney regeneration versus atrophy. J Am Soc Nephrol. 2014;25:292-304 31. Ko GJ, Grigoryev DN, Linfert D, Jang HR, Watkins T, Cheadle C, et al. Transcriptional analysis of kidneys during repair from aki reveals possible roles for ngal and kim-1 as biomarkers of aki-to-ckd transition. Am J Physiol Renal Physiol. 2010;298:F1472-83 32. Newsome BB, Warnock DG, McClellan WM, Herzog CA, Kiefe CI, Eggers PW, et al. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med. 2008;168:609-16 33. Sato Y, Mii A, Hamazaki Y, Fujita H, Nakata H, Masuda K, et al. Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney. JCI Insight. 2016;1:e87680 34. Humphreys BD, Czerniak S, DiRocco DP, Hasnain W, Cheema R, Bonventre JV. Repair of injured proximal tubule does not involve specialized progenitors. Proc Natl Acad Sci U S A. 2011;108:9226-31 35. Endo T, Nakamura J, Sato Y, Asada M, Yamada R, Takase M, et al. Exploring the origin and limitations of kidney regeneration. J Pathol. 2015;236:251-63 36. Cheng SY, Chou YH, Liao FL, Lin CC, Chang FC, Liu CH, et al. Losartan reduces ensuing chronic kidney disease and mortality after acute kidney injury. Sci Rep. 2016;6:34265 37. Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol. 2002;13:2916-29 38. Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK. Acute kidney injury: A springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol. 2010;298:F1078-94 39. Conger JD, Robinette JB, Hammond WS. Differences in vascular reactivity in models of ischemic acute renal failure. Kidney Int. 1991;39:1087-97 40. Yamamoto T, Tada T, Brodsky SV, Tanaka H, Noiri E, Kajiya F, et al. Intravital videomicroscopy of peritubular capillaries in renal ischemia. Am J Physiol Renal Physiol. 2002;282:F1150-5 41. Chen X, Wang CC, Song SM, Wei SY, Li JS, Zhao SL, et al. The administration of erythropoietin attenuates kidney injury induced by ischemia/reperfusion with increased activation of wnt/beta-catenin signaling. J Formos Med Assoc. 2015;114:430-7 42. Lin SL, Chang FC, Schrimpf C, Chen YT, Wu CF, Wu VC, et al. Targeting endothelium-pericyte cross talk by inhibiting vegf receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol. 2011;178:911-23 43. Schrimpf C, Xin C, Campanholle G, Gill SE, Stallcup W, Lin SL, et al. Pericyte timp3 and adamts1 modulate vascular stability after kidney injury. J Am Soc Nephrol. 2012;23:868-83 44. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60 45. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9 46. Cao W, Jin L, Zhou Z, Yang M, Wu C, Wu L, et al. Overexpression of intrarenal renin-angiotensin system in human acute tubular necrosis. Kidney Blood Press Res. 2016;41:746-56 47. Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-angiotensin system in kidney physiology. Compr Physiol. 2014;4:1201-28 48. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251-87 49. Kontogiannis J, Burns KD. Role of at1 angiotensin ii receptors in renal ischemic injury. Am J Physiol. 1998;274:F79-90 50. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006;17:2985-91 51. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F. Angiotensin ii activates nuclear transcription factor-kappab through at1 and at2 receptors. Kidney Int. 2002;61:1986-95 52. Wolf G, Bohlender J, Bondeva T, Roger T, Thaiss F, Wenzel UO. Angiotensin ii upregulates toll-like receptor 4 on mesangial cells. J Am Soc Nephrol. 2006;17:1585-93 53. Ruiz-Ortega M, Esteban V, Ruperez M, Sanchez-Lopez E, Rodriguez-Vita J, Carvajal G, et al. Renal and vascular hypertension-induced inflammation: Role of angiotensin ii. Curr Opin Nephrol Hypertens. 2006;15:159-66 54. Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, et al. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol. 2005;16:2702-13 55. Wolf G. Link between angiotensin ii and tgf-beta in the kidney. Miner Electrolyte Metab. 1998;24:174-80 56. Abrahamsen CT, Pullen MA, Schnackenberg CG, Grygielko ET, Edwards RM, Laping NJ, et al. Effects of angiotensins ii and iv on blood pressure, renal function, and pai-1 expression in the heart and kidney of the rat. Pharmacology. 2002;66:26-30 57. Rodriguez-Romo R, Benitez K, Barrera-Chimal J, Perez-Villalva R, Gomez A, Aguilar-Leon D, et al. At1 receptor antagonism before ischemia prevents the transition of acute kidney injury to chronic kidney disease. Kidney Int. 2016;89:363-73 58. Bellomo R, Auriemma S, Fabbri A, D'Onofrio A, Katz N, McCullough PA, et al. The pathophysiology of cardiac surgery-associated acute kidney injury (csa-aki). Int J Artif Organs. 2008;31:166-78 59. Yang X, Chen C, Tian J, Zha Y, Xiong Y, Sun Z, et al. Urinary angiotensinogen level predicts aki in acute decompensated heart failure: A prospective, two-stage study. J Am Soc Nephrol. 2015;26:2032-41 60. Hsu CY, Hsu RK, Yang J, Ordonez JD, Zheng S, Go AS. Elevated bp after aki. J Am Soc Nephrol. 2016;27:914-23 61. Zhang J, Rudemiller NP, Patel MB, Wei Q, Karlovich NS, Jeffs AD, et al. Competing actions of type 1 angiotensin ii receptors expressed on t lymphocytes and kidney epithelium during cisplatin-induced aki. J Am Soc Nephrol. 2016;27:2257-64 62. Benedetto U, Sciarretta S, Roscitano A, Fiorani B, Refice S, Angeloni E, et al. Preoperative angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting. Ann Thorac Surg. 2008;86:1160-5 63. Arora P, Rajagopalam S, Ranjan R, Kolli H, Singh M, Venuto R, et al. Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol. 2008;3:1266-73 64. Morris BJ, Cantanzaro DF, Hardman J, Mesterovic N, Tellam J, Hort Y, et al. Human renin gene sequence, gene regulation and prorenin processing. J Hypertens Suppl. 1984;2:S231-3 65. Field LJ, McGowan RA, Dickinson DP, Gross KW. Tissue and gene specificity of mouse renin expression. Hypertension. 1984;6:597-603 66. Buys ES, Raher MJ, Kirby A, Shahid M, Baron DM, Hayton SR, et al. Genetic modifiers of hypertension in soluble guanylate cyclase alpha1-deficient mice. J Clin Invest. 2012;122:2316-25 67. Sigmund CD, Gross KW. Structure, expression, and regulation of the murine renin genes. Hypertension. 1991;18:446-57 68. Cheungpasitporn W, Thongprayoon C, Srivali N, O'Corragain OA, Edmonds PJ, Ungprasert P, et al. Preoperative renin-angiotensin system inhibitors use linked to reduced acute kidney injury: A systematic review and meta-analysis. Nephrol Dial Transplant. 2015;30:978-88 69. Kumar AB, Suneja M, Bayman EO, Weide GD, Tarasi M. Association between postoperative acute kidney injury and duration of cardiopulmonary bypass: A meta-analysis. J Cardiothorac Vasc Anesth. 2012;26:64-9 70. Chang YT, Yang CC, Pan SY, Chou YH, Chang FC, Lai CF, et al. DNA methyltransferase inhibition restores erythropoietin production in fibrotic murine kidneys. J Clin Invest. 2016;126:721-31 71. Chiang WC, Lai CF, Su CT, Peng WH, Wu CF, Chang FC, et al. Angiopoietins modulate endothelial adaptation, glomerular and podocyte hypertrophy after uninephrectomy. PLoS One. 2013;8:e82592 72. Chen LI, Guh JY, Wu KD, Chen YM, Kuo MC, Hwang SJ, et al. Modification of diet in renal disease (mdrd) study and ckd epidemiology collaboration (ckd-epi) equations for taiwanese adults. PLoS One. 2014;9:e99645 73. Zuk A, Bonventre JV. Acute kidney injury. Annu Rev Med. 2016;67:293-307 74. Rewa O, Bagshaw SM. Acute kidney injury-epidemiology, outcomes and economics. Nat Rev Nephrol. 2014;10:193-207 75. Finkenstaedt JT, Merrill JP. Renal function after recovery from acute renal failure. N Engl J Med. 1956;254:1023-6 76. Wu VC, Wu CH, Huang TM, Wang CY, Lai CF, Shiao CC, et al. Long-term risk of coronary events after aki. J Am Soc Nephrol. 2014;25:595-605 77. K/doqi clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1-290 78. de Caestecker M, Humphreys BD, Liu KD, Fissell WH, Cerda J, Nolin TD, et al. Bridging translation by improving preclinical study design in aki. J Am Soc Nephrol. 2015;26:2905-16 79. Joo JD, Kim M, D'Agati VD, Lee HT. Ischemic preconditioning provides both acute and delayed protection against renal ischemia and reperfusion injury in mice. J Am Soc Nephrol. 2006;17:3115-23 80. Takase O, Marumo T, Imai N, Hirahashi J, Takayanagi A, Hishikawa K, et al. Nf-kappab-dependent increase in intrarenal angiotensin ii induced by proteinuria. Kidney Int. 2005;68:464-73 81. Miyata K, Ohashi N, Suzaki Y, Katsurada A, Kobori H. Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2008;35:922-7 82. Spurgeon-Pechman KR, Donohoe DL, Mattson DL, Lund H, James L, Basile DP. Recovery from acute renal failure predisposes hypertension and secondary renal disease in response to elevated sodium. Am J Physiol Renal Physiol. 2007;293:F269-78 83. Graham D, McBride MW, Gaasenbeek M, Gilday K, Beattie E, Miller WH, et al. Candidate genes that determine response to salt in the stroke-prone spontaneously hypertensive rat: Congenic analysis. Hypertension. 2007;50:1134-41 84. Wei SY, Wang YX, Zhang QF, Zhao SL, Diao TT, Li JS, et al. Multiple mechanisms are involved in salt-sensitive hypertension-induced renal injury and interstitial fibrosis. Sci Rep. 2017;7:45952 85. Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, Ordonez JD, et al. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int. 2009;76:893-9 86. Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA. 2009;302:1179-85 87. Amdur RL, Chawla LS, Amodeo S, Kimmel PL, Palant CE. Outcomes following diagnosis of acute renal failure in u.S. Veterans: Focus on acute tubular necrosis. Kidney Int. 2009;76:1089-97 88. Ma LJ, Fogo AB. Model of robust induction of glomerulosclerosis in mice: Importance of genetic background. Kidney Int. 2003;64:350-5 89. Chang FC, Chiang WC, Tsai MH, Chou YH, Pan SY, Chang YT, et al. Angiopoietin-2-induced arterial stiffness in ckd. J Am Soc Nephrol. 2014;25:1198-209 90. Polichnowski AJ, Lan R, Geng H, Griffin KA, Venkatachalam MA, Bidani AK. Severe renal mass reduction impairs recovery and promotes fibrosis after aki. J Am Soc Nephrol. 2014;25:1496-507 91. Alvarez A, Cerda-Nicolas M, Naim Abu Nabah Y, Mata M, Issekutz AC, Panes J, et al. Direct evidence of leukocyte adhesion in arterioles by angiotensin ii. Blood. 2004;104:402-8 92. Kitayama H, Maeshima Y, Takazawa Y, Yamamoto Y, Wu Y, Ichinose K, et al. Regulation of angiogenic factors in angiotensin ii infusion model in association with tubulointerstitial injuries. Am J Hypertens. 2006;19:718-27 93. Dai Q, Xu M, Yao M, Sun B. Angiotensin at1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol. 2007;152:1042-8 94. Wu K, Zhou T, Sun G, Wang W, Zhang Y, Zhang Y, et al. Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue. Cell Mol Immunol. 2006;3:213-20 95. Xu Z, Li W, Han J, Zou C, Huang W, Yu W, et al. Angiotensin ii induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (md2). Sci Rep. 2017;7:44911 96. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, et al. Human t and natural killer cells possess a functional renin-angiotensin system: Further mechanisms of angiotensin ii-induced inflammation. J Am Soc Nephrol. 2007;18:1093-102 97. Crowley SD, Frey CW, Gould SK, Griffiths R, Ruiz P, Burchette JL, et al. Stimulation of lymphocyte responses by angiotensin ii promotes kidney injury in hypertension. Am J Physiol Renal Physiol. 2008;295:F515-24 98. Okada H, Inoue T, Kanno Y, Kobayashi T, Watanabe Y, Kopp JB, et al. Interstitial fibroblast-like cells express renin-angiotensin system components in a fibrosing murine kidney. Am J Pathol. 2002;160:765-72 99. Ruiz-Ortega M, Egido J. Angiotensin ii modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int. 1997;52:1497-510 100. Macedo E, Zanetta DM, Abdulkader RC. Long-term follow-up of patients after acute kidney injury: Patterns of renal functional recovery. PLoS One. 2012;7:e36388 101. Macedo E, Bouchard J, Mehta RL. Renal recovery following acute kidney injury. Curr Opin Crit Care. 2008;14:660-5 102. Bellomo R. Defining, quantifying, and classifying acute renal failure. Crit Care Clin. 2005;21:223-37 103. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA. 2005;294:813-8 104. Thiele RH, Isbell JM, Rosner MH. Aki associated with cardiac surgery. Clin J Am Soc Nephrol. 2015;10:500-14 105. Rosner MH, Portilla D, Okusa MD. Cardiac surgery as a cause of acute kidney injury: Pathogenesis and potential therapies. J Intensive Care Med. 2008;23:3-18 106. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16:3365-70 107. Horbelt M, Lee SY, Mang HE, Knipe NL, Sado Y, Kribben A, et al. Acute and chronic microvascular alterations in a mouse model of ischemic acute kidney injury. Am J Physiol Renal Physiol. 2007;293:F688-95 108. Rosen S, Stillman IE. Acute tubular necrosis is a syndrome of physiologic and pathologic dissociation. J Am Soc Nephrol. 2008;19:871-5 109. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527-39 110. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM, et al. 2017 acc/aha/hfsa focused update of the 2013 accf/aha guideline for the management of heart failure: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of america. Circulation. 2017 111. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012;308:2108-17 112. McClellan WM, Flanders WD. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol. 2003;14:S65-70 113. Walsh M, Garg AX, Devereaux PJ, Argalious M, Honar H, Sessler DI. The association between perioperative hemoglobin and acute kidney injury in patients having noncardiac surgery. Anesth Analg. 2013;117:924-31 114. Sawhney S, Mitchell M, Marks A, Fluck N, Black C. Long-term prognosis after acute kidney injury (aki): What is the role of baseline kidney function and recovery? A systematic review. BMJ Open. 2015;5:e006497 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59518 | - |
dc.description.abstract | 急性腎損傷近年在台灣及全球逐年增加,許多研究發現急性腎損傷會造成許多併發症與較高死亡率,急性腎損傷也會造成慢性腎臟病的產生,兩者互為因果關係,慢性腎臟病的產生與急性腎損傷的嚴重程度、持續時間長短與發生次數有正相關,過去認為急性腎損傷只要不要太嚴重都可恢復且不會有後遺症的想法是錯的,許多研究已發現即使急性腎損傷恢復後仍會增加後續慢性腎臟病的產生,但目前的研究多著重於如何避免與減少急性腎損傷的產生與傷害程度,對於急性腎損傷進展到慢性腎臟病的機轉尚未十分清楚且對於這些病人臨床的照顧指引仍無共識。
我們在CD-1和C57BL/6老鼠建立急性腎損傷轉變為慢性腎臟病的動物模式,CD-1老鼠有兩套renin基因分別是Ren1、Ren2,腎素-血管收縮素系統活性應比較高,而C57BL/6老鼠只有一套renin基因是Ren1與人類相同,我們先進行右側腎摘除2星期後,將左側腎進行缺血性再灌流傷害,儘管一個月後血中肌酸酐已恢復正常但組織切片仍看到腎小管、腎絲球萎縮、間質有發炎細胞浸潤及纖維母細胞增生合併纖維化的表現,追蹤5-8個月後出現肌酸酐再度逐漸上升、血壓增加、蛋白尿增加的情形,這些變化在CD-1老鼠較快發生,而C57BL/6較晚才會發生,分析腎素-血管收縮素系統相關基因表現都有增加,代表腎素-血管收縮素系統在急性腎損傷後一個月仍有活性增加的情形。 急性腎損傷後一個月我們將老鼠分為三群分別給予一般飲水、含losartan (anti-Type-1A angiotensin II receptor antagonist)的飲水、含hydralazine (vasodilator with anti-hypertensive effect)的飲水,加上一組控制組僅單側腎切除後給予一般飲水,共觀察5-8個月後分析結果,給予losartan那組的老鼠死亡率比較低且比較不會有血壓增加、腎功能變差、蛋白尿增加與纖維化的情形,給予hydralazine那組的老鼠雖然血壓沒有增加,但其他病理表現都比給予losartan那組的老鼠嚴重。 我們進一步想根據動物實驗的結果來看臨床病人急性腎損傷功能恢復後給予腎素-血管收縮素系統的抑制劑是否可減少後續慢性腎病變的產生,我們研究接受心臟手術術後發生急性腎損傷的病人,因為心臟手術造成急性腎損傷的機轉與我們的動物實驗較相似,病人的納入條件為1.術前無慢性腎臟病且未服用腎素-血管收縮素系統抑制劑;2.發生急性腎損傷且血中肌酸酐恢復正常後才開始使用腎素-血管收縮素系統抑制劑。 共有587人符合收案資格,病人平均追蹤2.99年,我們發現有使用腎素-血管收縮素系統抑制劑的病人較不會產生慢性腎臟病 (26.6% vs. 42.2%, p = 0.005),且使用腎素-血管收縮素系統抑制劑的病人需較久的時間才會產生慢性腎臟病 (1079 days vs. 520 days, p = 0.01),多項式迴歸分析指出使用腎素-血管收縮素系統抑制劑是降低急性腎損傷後產生慢性腎臟病的獨立相關因子 (風險比率 = 0.46, p < 0.001),這些發現可作為之後大型臨床雙盲試驗的參考,並提供預防急性腎損傷轉變為慢性腎臟病治療的參考指引,我們也將進一步探究腎素-血管收縮素系統抑制劑在急性腎損傷的其他病生理的影響。 | zh_TW |
dc.description.abstract | Acute kidney injury (AKI) is common and associated with higher morbidity and mortality globally. AKI has also been recognized as a major risk factor for the development of chronic kidney disease (CKD). Mounting evidence has shown that AKI and CKD appear to be an interconnected syndrome. The severity, duration and frequency of AKI has been linked to the development and progression of ensuing CKD. The previous conventional wisdom that AKI survivors with fully recovered renal function tend to do well appears to be flawed. Clinical studies disclose that ensuing CKD progresses after functional recovery from AKI. Continuous monitoring of renal function should be emphasized, even if patients have shown functional recovery after AKI. Many studies have focused on the prevention and management of AKI to reduce the ensuing CKD development. Nevertheless, more efforts are needed to develop strategies for blocking AKI-CKD transition after functional recovery.
We demonstrated AKI-CKD continuum in murine model of CD-1 and C57BL/6 mice. CD-1 mice have Ren1 and Ren2 gene which is supposed to have higher RAS activity. C57BL/6 mice have only Ren1 gene that is similar to humans. We performed left renal ischemia-reperfusion injury 2 weeks after right nephrectomy in both male murine model. Despite functional recovery, focal tubular atrophy, interstitial cell infiltration and fibrosis, upregulation of genes encoding angiotensinogen and AT1a receptor were shown in kidneys 4 weeks after AKI. Thereafter, mice manifested increase of blood pressure, albuminuria and azotemia progressively. C57BL/6 mice exhibited increase of blood pressure and azotemia progressively as well, but in a slower rate than CD-1 mice. Subsequently, drinking water with or without losartan or hydralazine was administered to mice from 4 weeks after AKI. Increase of mortality, blood pressure, albuminuria, azotemia and kidney fibrosis was noted in mice with vehicle administration during the 5 to 8 month experimental period. On the contrary, these parameters in mice with losartan administration were reduced to the levels shown in control group. Hydralazine did not provide similar beneficial effect though blood pressure was controlled. These findings demonstrated that losartan can reduce ensuing CKD and mortality after functional recovery from AKI. To get insight into the clinical application of RAS inhibitor and its impact on development of ensuing CKD in AKI survivors with complete renal recovery, we studied the outcomes and relevant risk factors of cardiac surgery–associated AKI (CSA-AKI) patients who did not have CKD history before surgery in our retrospective observational cohort. Patients with CKD, unrecovered AKI, and use of RAS inhibitor before surgery are excluded. Among 587 eligible patients, 94 patients are users of RAS inhibitor which is started and continued after complete renal recovery during median follow-up period of 2.99 years. The users of RAS inhibitor show significantly lower rate of ensuing CKD (users vs. non-users, 26.6% vs. 42.2%, p = 0.005) and longer median CKD-free survival time (users vs. non-users, 1079 days vs. 520 days, p = 0.01). Multivariate Cox regression analyses further demonstrate that use of RAS inhibitor is independently associated with lower risk of ensuing CKD (hazard ratio = 0.46, p < 0.001). We conclude that use of RAS inhibitor in CSA-AKI patients after renal functional recovery is associated with lower risk of ensuing CKD development. From bench to clinical study, RAS blockade seems to be a potential treatment to prevent AKI-CKD continuum. Further elucidation of RAS effect on renal recovery and randomized-controlled clinical study should be initiated in the future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T09:26:23Z (GMT). No. of bitstreams: 1 ntu-106-D02441003-1.pdf: 4711752 bytes, checksum: f302280ad3200f5a2cd9e4e9036110cf (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員審定書 i
誌謝 ii 中文摘要 iii Abstract v Table of contents目錄………………………………………………………….…..….vii Table of figures and tables x Abbreviations xii Chapter 1. Introduction 1 1.1. Definition and epidemiology of acute kidney injury and chronic kidney disease.. 1 1.2. Ischemia-reperfusion AKI 3 1.2.1. Causes 3 1.2.2. Pathophysiology 4 1.3. AKI-CKD continuum 6 1.3.1. Epidemiology of AKI-CKD continuum 6 1.3.2. The mechanisms of AKI-CKD continuum 7 1.4. The renin angiotensin system (RAS) 13 1.4.1. Physiological actions of the RAS in the kidney 14 1.4.2. The role of intrarenal RAS in AKI-CKD continuum 16 1.4.3. Renin gene in different species 19 1.5. Animal models of AKI-CKD continuum 20 1.5.1. Nephrectomy (Nx) and ischemia-reperfusion injury (IRI) 21 1.6. Clinical cohort study of AKI 21 1.6.1. Cardiac surgery-associated AKI (CSA-AKI) 21 1.7. The aim of the study 22 1.7.1. Establish an optimal murine model of AKI-CKD continuum. 22 1.7.2. Clarify the status of intrarenal RAS in murine model of AKI-CKD continuum 22 1.7.3. Evaluate the effect of RAS inhibition on AKI-CKD continuum in murine model…22 1.7.4. Evaluate the effect of RAS inhibition on AKI-CKD continuum in AKI patients 22 Chapter 2. Material and Method 23 2.1. Materials of animal study 23 2.1.1. Animals 23 2.1.2. RAS inhibitor: Losartan 23 2.1.3. Antihypertensive agent : Hydralazine 24 2.1.4. Chemicals 24 2.1.5. Buffer 29 2.1.6. Antibodies 31 2.1.7. Instruments 33 2.2. Methods of animal study 34 2.2.1. Animal model of AKI 34 2.2.2. Experimental groups 35 2.2.3. Blood pressure analyses in mice 36 2.2.4. Biochemical analyses of mouse plasma and urine 37 2.2.5.Tissue preparation and histology 37 2.2.6. Statistical analysis 40 2.3. Materials of clinical study 41 2.3.1. Study population 41 2.4. Methods of clinical study 42 2.4.1 Clinical assessment of patients 42 2.4.2 Outcome 44 2.4.3 Statistical analysis 44 Chapter 3. Result 45 3.1. Establish a murine model of AKI-CKD continuum after renal functional recovery……………………………………………………………………………………...45 3.1.1. Abnormal renal pathology and ongoing injury after functional recovery 47 3.1.2. Activation of RAS in repaired kidney after functional recovery from AKI 48 3.1.3. Elevated blood pressure after functional recovery from AKI 49 3.1.4. AKI-CKD continuum develops both in C57BL/6 and CD-1 mice but with different time course 49 3.1.5. Losartan reduces mortality and ensuing CKD after AKI. 50 3.1.6. Losartan decreases inflammation after AKI 52 3.1.7. Losartan attenuates fibrosis in ensuing CKD after AKI.. 53 3.2. Observational cohort study of CSA-AKI patients 53 3.2.1. Enrollement and clinical characteristics of patients 53 3.2.2.Development of ensuing CKD during follow-up. 54 3.2.3.Cox regression analyses of risk factors for CKD Development 55 3.2.4.Subgroup analysis for ensuing CKD associated with use of RAS inhibitor 55 Chapter 4. Discussion 57 Chapter 5. Conclusion and future prospects 72 Chapter 6. References .105 | |
dc.language.iso | en | |
dc.title | 腎素-血管收縮素系統在缺血再灌流急性腎損傷後進展成慢性腎臟病所扮演的角色 | zh_TW |
dc.title | The role of renin-angiotensin system in ischemia-reperfusion acute kidney injury–chronic kidney disease continuum | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 吳明修,陳永昌,楊鎧鍵 | |
dc.subject.keyword | 腎素-血管收縮素系統,急性腎損傷,慢性腎臟病,缺血性再灌流傷害,腎臟再生,腎臟功能性恢復, | zh_TW |
dc.subject.keyword | renin-angiotensin system,acute kidney injury,chronic kidney disease,ischemia-reperfusion injury,renal regeneration,renal functional recovery, | en |
dc.relation.page | 114 | |
dc.identifier.doi | 10.6342/NTU201700892 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-06-05 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生理學研究所 | zh_TW |
顯示於系所單位: | 生理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 4.6 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。